{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-073836","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.515852+00:00","generated_at":"2026-06-13T19:02:52.092690+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Hepion Pharma stockholders elect all director nominees, ratify BDO, approve equity plan, pass say-on-pay","bullets":["All seven director nominees elected; votes For ranged from 15.7M (Jacob) to 20.7M (Wijngaard).","Ratification of BDO USA as auditors passed with 32.5M For, 8.3M Against, 0.8M abstain.","2023 Omnibus Equity Incentive Plan approved with 14.4M For, 12.0M Against, 0.3M abstain.","Advisory say-on-pay proposal passed with 14.2M For, 12.2M Against, 0.4M abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-073836","json":"https://secwatch.observer/filing/0001104659-23-073836.json","markdown":"https://secwatch.observer/filing/0001104659-23-073836.md","text":"https://secwatch.observer/filing/0001104659-23-073836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/tm2319442d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:02:52.092690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"233c9d000712f6a500207f437a167bfc087f4386","claim":"Hepion Pharmaceuticals, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company's named executive officers at the 2023-06-22 meeting.","evidence_excerpt":"To approve, on an advisory basis, the compensation of the Company’s named executive officers, referred to as “say-on-pay.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"a386c2fad2d2c3e54076e896d613f0b02ac2e446","claim":"Hepion Pharmaceuticals, Inc. shareholders approved Election of seven directors at the 2023-06-22 meeting.","evidence_excerpt":"To elect the seven (7) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified including Gary S. Jacob, Robert Foster, John P. Brancaccio, Timothy Block, Peter Wijngaard, Anand Reddi and Kaouthar Lbiati.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"a822ad29243dda71bd3dd5dc1717995265a1a2a1","claim":"Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of BDO USA, LLP as the Company's independent auditors for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.","evidence_excerpt":"To ratify the appointment of BDO USA, LLP as the Company’s independent auditors for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"ca966a7ca8de7b8922f522889458d7946cdb3e94","claim":"Hepion Pharmaceuticals, Inc. shareholders approved Approve the Company's 2023 Omnibus Equity Incentive Plan at the 2023-06-22 meeting.","evidence_excerpt":"To approve the Company’s 2023 Omnibus Equity Incentive Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923073836/0001104659-23-073836-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}